Since the start of the anti-Covid vaccination campaigns, almost two and a half years ago, many women have reported disturbances in their menstrual cycles.
Published
Reading time: 1 min
:quality(50)/2024/01/24/000-33xj73q-65b10c7371912783023779.jpg)
The risk of menstrual disorders is slightly increased during the three months following the administration of an anti-Covid messenger RNA vaccine, suggests a study released on Wednesday January 24 by the French health authorities, while such a link remains debated in the scientific community.
The study “highlights a 20% increase in the risk of heavy menstrual bleeding requiring hospital treatment within 1 to 3 months” after having received a Pfizer or Moderna vaccine for the first time, summarizes in a press release the Epi-Phare organization, which brings together the medicines authority (ANSM) and Social Security.
A risk that lasts three months and then disappears
Since the start of anti-Covid vaccination campaigns, almost two and a half years ago, many women have reported disruptions in their menstrual cycles. Based on these statements, the European Medicines Agency (EMA) notably ended up including the presence of heavy menstrual bleeding as a possible side effect of messenger RNA vaccines, those from Pfizer/BioNTech and Moderna.
However, studies on the subject remain contradictory and that of Epi-Phare provides arguments for those in favor of the existence of such a link. The researchers identified the vaccination status of several thousand women hospitalized for heavy menstrual bleeding in 2021 and 2022. They compared their situation to a control group of women who had not been treated for this reason.
Ultimately, they conclude that the risk of such a menstrual disorder is slightly higher the first time a woman receives a Moderna or Pfizer vaccine, each administered in two successive doses. The risk lasts for three months and then, even after a subsequent booster dose, disappears.
